For lung carcinoma therapy, knowledge of the following is essential: histopathological type of the tumour, ist grade of differentiation (grading) and ist stage (stating), but lately also ist classification and subtype on the molecular-biological and cytogenetic levels. Today´s pathologists have to evaluate not only the histological singns, but also the prognostic and predictive markers, which are decisive in regards to the use and efficacy of classic chemotherapy or application of targeted biological therapy.